Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

A fourth subsidiary of OxStem Ltd, an Oxford spin-out co-founded by Professor Steve Davies and Professor Angela Russell has been launched.

 OxStem Cardio, co-founded with Prof. Roger Patient (Professor of Developmental Genetics Weatherall Institute of Molecular Medicine) and Professor Paul Riley (British Heart Foundation Professor of Regenerative Medicine), aims to identify drugs that will restore lost tissue following a heart attack by inducing cardiovascular regeneration, in order to improve cardiac function. This collaborative project will be funded within the University over the next three years following OxStem’s record £16.9M initial fundraise earlier this year.

Similar stories

New research to radically alter our understanding of synaptic development

Publication Research

A new study from the Molnár group on the role of regulated synaptic vesicular release in specialised synapse formation has made it to the cover of Cerebral Cortex.

Being "in the zone": how waking activity controls sleep need

Publication Research Vyazovskiy Group News

A new study from the Vyazovskiy group suggests that how and where we spend our time while awake impacts how much we need to sleep - it does not only depend on how long we are awake.

New target identified to develop treatment for Abdominal Aortic Aneurysm

Cardiac Theme Publication Research

A new study from the Smart group has shed light on a key regulatory step in the initiation and progression of Abdominal Aortic Aneurysm by revealing the protective role of a previously little known small protein.

Drug trial that could improve respiratory recovery from COVID-19 now underway

Research

A clinical trial has commenced this week to test whether a drug called almitrine can help people who are seriously ill with COVID-19 to recover from the disease.